U.S. patent application number 11/305293 was filed with the patent office on 2006-06-22 for cosmetic composition.
This patent application is currently assigned to L'OREAL. Invention is credited to Angeles Fonolla Moreno, Bertrand Piot.
Application Number | 20060134234 11/305293 |
Document ID | / |
Family ID | 36596139 |
Filed Date | 2006-06-22 |
United States Patent
Application |
20060134234 |
Kind Code |
A1 |
Fonolla Moreno; Angeles ; et
al. |
June 22, 2006 |
Cosmetic composition
Abstract
The invention relates to a composition containing, preferably in
a physiologically acceptable medium, at least one xanthine base or
a plant extract containing it, at least one polyurethane powder,
and at least one non-ionic dimethicone copolyol. The invention also
relates to a cosmetic method for combating cellulite and/or
"orange-peel" skin and/or slimming the figure, comprising the
application of the composition to the skin. The composition applied
to the skin exhibits good cosmetic properties of softness and of
non-tackiness.
Inventors: |
Fonolla Moreno; Angeles;
(Paris, FR) ; Piot; Bertrand; (Paris, FR) |
Correspondence
Address: |
OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C.
1940 DUKE STREET
ALEXANDRIA
VA
22314
US
|
Assignee: |
L'OREAL
14, rue Royale
Paris
FR
75008
|
Family ID: |
36596139 |
Appl. No.: |
11/305293 |
Filed: |
December 19, 2005 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
60640239 |
Jan 3, 2005 |
|
|
|
Current U.S.
Class: |
424/729 ;
424/776; 514/263.34 |
Current CPC
Class: |
A61K 36/185 20130101;
A61K 36/82 20130101; A61K 36/74 20130101; A61K 2300/00 20130101;
A61K 2300/00 20130101; A61K 2300/00 20130101; A61K 2300/00
20130101; A61K 2300/00 20130101; A61K 2300/00 20130101; A61K 31/522
20130101; A61P 17/00 20180101; A61K 31/60 20130101; A61K 31/60
20130101; A61K 36/185 20130101; A61K 36/82 20130101; A61K 36/74
20130101; A61K 36/77 20130101; A61K 36/77 20130101; A61K 31/522
20130101 |
Class at
Publication: |
424/729 ;
424/776; 514/263.34 |
International
Class: |
A61K 36/82 20060101
A61K036/82; A61K 31/522 20060101 A61K031/522 |
Foreign Application Data
Date |
Code |
Application Number |
Dec 17, 2004 |
FR |
04 53051 |
Claims
1. A composition comprising, in a physiologically acceptable
medium, at least one xanthine base and/or at least one plant
extract comprising a xanthine base, at least one polyurethane
powder, and at least one non-ionic dimethicone copolyol.
2. The composition according to claim 1, comprising at least one
xanthine base chosen from: caffeine, theophylline, theobromine,
acefylline, xanthinol nicotinate, diniprophylline, diprophylline,
etamiphylline and its derivatives, etophylline, proxyphylline,
pentophylline, propentophylline, pyridophylline and
bamiphylline.
3. The composition according to claim 1, comprising at least one
xanthine base chosen from: caffeine, theophylline, theobromine and
acefylline.
4. The composition according to claim 1, comprising at least one
plant extract comprising a xanthine base chosen from: plant
extracts of tea, of coffee, of guarana, of mate and of cola.
5. The composition according to claim 1, wherein the xanthine base
is present in an amount ranging from 0.01% to 10% by weight,
relative to the total weight of the composition
6. The composition according to claim 1, wherein the polyurethane
powder is not film-forming.
7. The composition according to claim 1, wherein the polyurethane
powder is a powder of a copolymer of hexamethylene diisocyanate and
of trimethylol hexyl lactone.
8. The composition according to claim 1, wherein it comprises a
polyurethane powder in an amount ranging from 0.5% to 10% by
weight.
9. The composition according to claim 1, wherein the non-ionic
dimethicone copolyol is an oxypropylenated and/or oxyethylenated
polydimethylmethylsiloxane that does not contain an ionic
group.
10. The composition according to claim 1, wherein the non-ionic
dimethicone copolyol is present in an amount ranging from 0.05% to
5% by weight.
11. The composition according to claim 1, wherein it further
comprises an aqueous phase comprising water.
12. The composition according to claim 11, wherein said composition
comprises water in an amount ranging from 30% to 80% by weight,
relative to the total weight of the composition.
13. The composition according to claim 11, wherein said aqueous
phase further comprises at least one monoalcohol having from 2 to 6
carbon atoms.
14. The composition according to claim 13, wherein said aqueous
phase comprises at least one of ethanol and isopropanol.
15. The composition according to claim 13, wherein the at least one
monoalcohol is present in an amount ranging from 1 to 30% by
weight, relative to the total weight of the composition.
16. The composition according to claim 1, wherein it comprises
salicylic acid or a derivative thereof.
17. The composition according to claim 16, wherein the salicylic
acid or derivative is present in an amount ranging from 0.1% to 5%
by weight, relative to the total weight of the composition.
18. The composition according to claim 1, wherein said composition
is in the form of an oil-in-water emulsion.
19. The composition according to claim 1, further comprising at
least one active agent chosen from active agents that act on
microcirculation, firming and/or anti-glycant active agents, and
mixtures thereof.
20. The composition according to claim 1, comprising, relative to
the total weight of the composition: 0.1% to 7% by weight of said
at least one xanthine base and/or said at least one plant extract
comprising a xanthine base; 0.5% to 6% by weight of said at least
one polyurethane powder; and 0.1% to 3% by weight of said at least
one non-ionic dimethicone copolyol, said composition further
comprising caffine and salicyclic acid.
Description
REFERENCE TO PRIOR APPLICATIONS
[0001] This application claims priority to U.S. provisional
application 60/640,239 filed Jan. 3, 2005, and to French patent
application 0453051 filed Dec. 17, 2004, both incorporated herein
by reference.
FIELD OF THE INVENTION
[0002] The present invention relates to a composition comprising at
least one dimethicone copolyol, at least one xanthine base and at
least one polyurethane powder. The invention also relates to a
method for combating cellulite and/or "orange-peel" skin and/or
slimming the figure, comprising the topical application of the
composition to the skin.
[0003] Additional advantages and other features of the present
invention will be set forth in part in the description that follows
and in part will become apparent to those having ordinary skill in
the art upon examination of the following or may be learned from
the practice of the present invention. The advantages of the
present invention may be realized and obtained as particularly
pointed out in the appended claims. As will be realized, the
present invention is capable of other and different embodiments,
and its several details are capable of modifications in various
obvious respects, all without departing from the present invention.
The description is to be regarded as illustrative in nature, and
not as restrictive.
BACKGROUND OF THE INVENTION
[0004] Adiposity (or excess fat in the subcutaneous cellular
tissue) can have many causes that are more or less complex.
[0005] Some skin cells, called adipocytes, contain variable amounts
of fats in the form of triglycerides, these triglycerides being
synthesized in vivo by the adipocytes themselves, according to
enzymatic-type reactions (lipogenesis), from the free fatty acids
and the glucose (after degradation of the latter to glycerol)
contained in the body and introduced therein through certain foods.
Now, in parallel, the triglycerides thus formed, and then stored,
in the adipocyte cells can also redecompose, still under the action
of specific enzymes (lipolysis) contained in these same cells, this
time releasing, firstly, fatty acids and, secondly, glycerol and/or
monoesters and/or diesters of glycerol. The fatty acids thus
released can then either diffuse in the body in order to be
consumed therein or converted in different ways, or can be taken up
again (immediately or a little later) by the adipocytes in order to
again generate triglycerides by lipogenesis.
[0006] If, for various reasons (overly rich food, inactivity,
ageing and the like), a substantial imbalance becomes established
in the body between lipogenesis and lipolysis, i.e., more
precisely, if the amounts of fats formed by lipogenesis become
appreciably and constantly greater than those which are eliminated
by lipolysis, an accumulation of triglycerides then takes place in
the adipocytes, which, if it becomes excessive, may be reflected
gradually by the appearance of thick skin, the surface of which is
often non-uniform ("orange-peel skin") and of more or less flaccid
or gelatinous consistency, finally giving the figure a general
ungraceful appearance which may evolve from a simple local excess
(lipodysmorphia) and the formation of cellulite, passing through a
certain level of stoutness and ending at real obesity.
[0007] Now, given in particular the deep discomfort, both physical
and aesthetic and sometimes psychological, that adiposity and
cellulite cause among individuals who are affected by them, in
particular among women, they nowadays constitute a condition that
is increasingly less well tolerated or accepted.
[0008] Solutions have therefore been proposed, in the prior art,
for intervening on fatty acid metabolism, which is, as has been
seen, one of the favoured targets in the control of this excess of
fats in adipocytes.
[0009] This can be modulated: [0010] either by blocking glucose
transport inside the adipocyte, which results, as has been seen, in
a decrease in fatty acids entering the adipocyte, [0011] or by
inhibition of lipoprotein lipase, [0012] or by activation of
triglyceride lipase (or hormone-sensitive lipase), generally by
stimulating cyclic AMP, for example by activation of adenyl
cyclase, or by causing accumulation thereof by inhibition of
phosphodiesterase.
[0013] Other biological approaches have been explored for acting on
the mechanism of lipogenesis and/or of lipolysis. It has thus been
proposed to use neuropeptide Y (NPY) receptor antagonists,
neuropeptide Y being a neuromediator involved in a certain number
of physiological processes and the involvement of which in the
regulation of lipolysis it has been possible to demonstrate (P.
Valet, J. Clin. Invest., 1990, 85, 291-295). It is also possible to
use .alpha..sub.2 receptor antagonists or alternatively
.beta.3-adrenergic receptor agonists.
[0014] The cosmetic compositions proposed to date for the purpose
of treating adiposity therefore contain "slimming" compounds which
act on one or more of the mechanisms mentioned above. Among these,
mention may more particularly be made of xanthine bases (i.e.
xanthine derivatives), such as theophylline, caffeine,
theobromine.
[0015] However, xanthine bases such as caffeine have the drawback
of conferring on the slimming compositions poor cosmetic properties
that are experienced by the user after application of the
composition to the skin. The treated skin exhibits a tacky effect,
feels taut and lacks softness: these harmful properties are not
satisfactory to the user.
SUMMARY OF THE INVENTION
[0016] One object of the present invention is to provide a
composition with a slimming action containing a xanthine base and
exhibiting good cosmetic properties after application of the
composition to the skin, in particular good properties of
non-tackiness and of softness.
[0017] The inventors have discovered that such a composition can be
obtained by using, with a xanthine base, a polyurethane powder and
a non-ionic dimethicone copolyol.
[0018] The composition applied to the skin does not exhibit any
tacky effect and gives the skin a pleasant feeling of softness,
without any effect of tautness. In addition, the composition
exhibits good slimming effectiveness.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0019] A primary subject of the invention is a composition
comprising, preferably in a physiologically acceptable medium, at
least one xanthine base and/or at least one plant extract
containing a xanthine base, at least one polyurethane powder and at
least one non-ionic dimethicone copolyol.
[0020] Another subject of the invention is a method for combating
cellulite and/or "orange-peel" skin and/or slimming the figure,
comprising the application to the skin of a composition as defined
above.
[0021] The composition according to the invention is most
preferably generally suitable for topical application to the skin,
and therefore preferably comprises a physiologically acceptable
medium, i.e. a medium compatible with the skin. It is preferably a
cosmetically acceptable medium, i.e. a medium that has a pleasant
colour, smell and feel, and that does not generate any unacceptable
discomfort (stinging, tautness, redness) that may put the consumer
off using this composition.
[0022] The composition according to the invention comprises at
least one xanthine base and/or a plant extract containing it.
[0023] Among xanthine bases that can be used according to the
invention, mention may be made of: caffeine, theophylline,
theobromine, acefylline, xanthinol nicotinate, diniprophylline,
diprophylline, etamiphylline and its derivatives, etophylline,
proxyphylline, pentophylline, propentophylline, pyridophylline and
bamiphylline, and their mixtures, without this list being
limiting.
[0024] Use is in particular preferably made of caffeine,
theophylline, theobromine and acefylline, and more particularly
caffeine. These xanthine bases are known to be inhibitors of
phosphodiesterase, which is the enzyme responsible for the
degradation of cAMP. By increasing the intracellular level of cAMP,
these xanthine bases promote lipolytic activity and therefore
constitute first-rate slimming active agents.
[0025] As examples of plant extracts containing xanthine bases,
mention may in particular be made of extracts of tea, of coffee, of
guarana, of mate and of cola, and their mixtures, without this list
being limiting.
[0026] The one or more xanthine bases may be present in the
composition according to the invention in any amount that is
effective for the desired purpose, for example an amount ranging
from 0.01% to 10% by weight, relative to the total weight of the
composition, preferably ranging from 0.1% to 7% by weight, and
preferentially ranging from 0.1% to 3% by weight, in particular
ranging from 1% to 3% by weight.
[0027] The composition according to the invention also contains at
least one polyurethane powder. In particular, the polyurethane
powder is preferably not film-forming, i.e. it does not form a
continuous film when it is deposited on a support such as the
skin.
[0028] Advantageously, the polyurethane powder is a powder of a
copolymer of hexamethylene diisocyanate and of trimethylol hexyl
lactone. Such a polyurethane powder is in particular sold under the
names "Plastic Powder D-400" and "Plastic Powder D-800" by the
company Toshiki.
[0029] Another polyurethane powder that may be used is that sold
under the name "Plastic Powder CS-400" by the company Toshiki.
[0030] The at least one polyurethane powder may be present in the
composition according to the invention in any amount that is
effective for the desired purpose, for example an amount ranging
from 0.5% to 10% by weight, relative to the total weight of the
composition, and preferably ranging from 0.5% to 6% by weight, and
preferentially ranging from 0.5% to 3% by weight.
[0031] The composition according to the invention also comprises at
least one non-ionic dimethicone copolyol.
[0032] The non-ionic dimethicone copolyol is an oxypropylenated
and/or oxyethylenated polydimethylmethylsiloxane which does not
contain any ionic groups (such as anionic, cationic or amphoteric
groups).
[0033] Non-ionic dimethicone copolyols are in particular described
in patent U.S. Pat. No. 4,268,499, the contents of which are
incorporated into this application by way of reference.
[0034] A particularly preferred form of dimethicone copolyol is
that sold under the name Dow Corning 5225C by the company Dow
Corning.
[0035] The one or more non-ionic dimethicone copolyol may be
present in the composition according to the invention in any amount
that is effective for the desired purpose, for example in an amount
ranging from 0.05% to 5% by weight, relative to the total weight of
the composition, preferably ranging from 0.1% to 3% by weight, and
preferentially ranging from 0.1% to 2% by weight.
[0036] The composition according to the invention may
advantageously comprise an aqueous phase.
[0037] For example, the composition may comprise water in an amount
ranging from 30% to 80% by weight, relative to the total weight of
the composition, preferably ranging from 40% to 70% by weight, and
preferentially ranging from 45% to 65% by weight.
[0038] The water may be normal water, a floral water such as
cornflower water and/or a mineral water such as eau de Vittel, eau
de Lucas or eau de La Roche Posay and/or a spring water, for
example.
[0039] The aqueous phase may comprise at least one monoalcohol
having from 2 to 6 carbon atoms., such as ethanol or isopropanol,
in particular in an amount ranging from 1% to 30% by weight,
relative to the total weight of the composition, and preferably
ranging from 5% to 20% by weight.
[0040] The aqueous phase may also comprise salicylic acid or one of
its derivatives such as n-octanoyl acid, in particular present in
an amount ranging from 0.1% to 5% by weight, relative to the total
weight of the composition, preferably ranging from 0.1% to 3% by
weight and preferentially ranging from 0.1% to 2% by weight.
[0041] While not bound by any particular theory, it is believed
that the preferred presence of at least one monoalcohol and of
salicylic acid in the aqueous phase promote good dissolving of the
xanthine base in the aqueous phase and therefore improve the
slimming effectiveness of the composition.
[0042] The composition according to the invention may be in any
form, including any of the, e.g., cosmetic, dermatological and/or
pharmaceutical forms normally used for topical application to the
skin, in particular in the form of an oil-in-water or water-in-oil
or multiple emulsion, that is optionally gelled, of a silicone
emulsion, of a microemulsion or nanoemulsion, of a liquid, pasty or
solid anhydrous product, or of a dispersion of oil in an aqueous
phase in the presence of spherules, it being possible for these
spherules to be polymeric nanoparticles such as nanospheres and
nanocapsules or, better still, lipid vesicles of ionic and/or
non-ionic type. Advantageously, the composition is in the form of
an oil-in-water emulsion.
[0043] The composition of the invention may be more or less fluid
and may have the appearance of a white or coloured cream, of an
ointment, of a milk, of a lotion, of a serum, of a paste, of a
mousse or of a gel. It may optionally be applied to the skin in the
form of an aerosol. It may also be in the form of a solid, and for
example in the form of a stick.
[0044] The composition of the invention may also contain the
adjuvants known in the cosmetic and dermatological fields such as
hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic
active agents, moisturizers (such as glycerol, propylene glycol,
butylene glycol, pentylene glycol, hexylene glycol, dipropylene
glycol or diethylene glycol), preserving agents, antioxidants,
solvents, fragrances, fillers, pigments, hydrophilic screening
agents, odour absorbers and dyestuffs. The amounts of these various
adjuvants are those conventionally used in the fields under
consideration and are, for example, from 0.01 to 20% of the total
weight of the composition. Depending on their nature, these
adjuvants can be introduced into the fatty phase, into the aqueous
phase, or into lipid vesicles and/or into nanoparticles.
[0045] When the composition according to the invention is an
emulsion, the proportion of the fatty phase can preferably range
from 5 to 50% by weight, and preferably from 5 to 30% by weight
relative to the total weight of the composition.
[0046] As fats that can be used in the invention, use may be made
for example of mineral oils, oils of animal origin, synthetic oils,
silicone oils and fluoro oils. Fatty acids, waxes and gums, and in
particular silicone gums, can also be used as fats.
[0047] The emulsifiers and co-emulsifiers optionally used in the
composition in the form of an emulsion include those chosen from
those known and used in the field under consideration. These
emulsifiers and co-emulsifiers are preferably present, in the
composition, in a proportion ranging from 0.3 to 20% by weight, and
preferably from 0.5 to 5% by weight relative to the total weight of
the composition. As emulsifiers and co-emulsifiers that can be used
in the invention, it is particularly advantageous to use the fatty
acid esters of a polyol such as PEG-100 stearate, PEG-50 stearate
and PEG-40 stearate; sorbitan tristearate, the oxyethylenated
sorbitan stearates available under the trade names Tween.RTM. 20 or
Tween.RTM. 60, for example; and mixtures thereof.
[0048] As hydrophilic gelling agents, mention may in particular be
made of carboxyvinyl polymers (carbomer), acrylic copolymers such
as acrylate/alkyl acrylate copolymers, polyacrylamides,
polysaccharides, natural gums and clays, and as lipophilic gelling
agents, mention may be made of modified clays such as bentones,
metal salts of fatty acids, and hydrophobic silica.
[0049] As active agents which will add to the action of the
slimming active agents according to the invention, use may in
particular be made of: [0050] active agents that act on the
microcirculation (vasoprotectors or vasodilators), such as
flavonoids, extracts of Gingko biloba, ruscogenins, esculosides,
escin extracted from horsechestnut, nicotinates, hesperidin methyl
chalcone, butcher's broom, essential oils of lavender or of
rosemary; [0051] firming active agents and/or anti-glycant active
agents (which prevent the binding of sugar to collagen fibres),
such as extracts of Centella asiatica and of St. Paul's wort, which
stimulate collagen synthesis, silicon, amadorine, vitamin C and its
derivatives and retinol and its derivatives; [0052] and mixtures
thereof.
[0053] Of course, those skilled in the art know to choose the
optional compound(s) to be added to the compositions according to
the invention, and also the concentration thereof, in such a way
that the advantageous properties intrinsically associated with the
compositions in accordance with the invention are not, or are not
substantially, adversely affected by the addition envisaged.
[0054] The composition defined above can be used to prevent or
combat cellulite and/or to refine the figure or the contours of the
face.
[0055] The invention will now be illustrated by means of the
following nonlimiting examples.
EXAMPLES 1 TO 4
[0056] 3 slimming compositions according to the invention (Examples
2 to 4) containing a non-ionic dimethicone copolyol and a
polyurethane powder, and a composition that is not part of the
invention (Example 1) containing an anionic dimethicone copolyol
and a silica powder, were prepared.
[0057] The composition was applied to the skin and the cosmetic
properties obtained were observed.
[0058] The contents are expressed in grams. TABLE-US-00001
COMPOSITION Example Example Example Example 1* 2 3 4 PHASE I Water
qs qs qs qs Acrylic gelling agent (1) 0.5 0.5 0.2 Xanthan gum 0.1
0.08 AMPS (2) 0.1 1 0.6 Glycerol 4 4 5 4 Propylene glycol 3 3 3 3
Caffeine 2.5 2.5 3 4 Salicylic acid 0.4 0.4 0.5 0.6 PHASE II
Dimethicone copolyol (3) 0 2 3 5 Volatile silicone oils 9 9 7 5
Pecosil PS-100 (4) 1 -- -- -- Silicone gums 0.5 0.5 1 2 Fragrance
0.4 0.4 0.5 0.5 PHASE III 1 Ethanol 12 12 16 18 PHASE IV
Polyurethane powder (5) 1 0.8 2 Silica 1 Cosmetic properties No
soft Soft Very Very effect. and soft soft The skin slippery skin,
skin, catches effect, no no and is not tacky tacky taut. tacky.
effect. effect. Tacky sensation. *example not part of the invention
(1) Carboxyvinyl polymer sold under the name "Carbopol 980" by the
company Noveon. (2) Polyacrylamidopropanesulphonic acid partially
neutralized with aqueous ammonia and crosslinked, sold under the
name "Hostacerin AMPS" by the company Clariant. (3) Mixture of
dimethicone copolyol/cyclopentadimethyl-siloxane/water (10/88/2)
sold under the name "Dow Corning 5225C Formulation Aid" by the
company Dow Corning. (4) Oxyethylenated polydimethylsiloxane
comprising a phosphate group, sold under the name "Pecosil PS-100"
by the company Phoenix Chemical. (5) Polyurethane powder sold under
the name "Plastic Powder D-400" by the company
[0059] It was noted that the compositions of Examples 2 to 4
according to the invention, after application to the skin, provide
a satisfactory softness and do not feel tacky, whereas the
composition of Example 1 that is not part of the invention confers
a tautness of the skin (no softness) and exhibits a tacky
appearance.
[0060] The above written description of the invention provides a
manner and process of making and using it such that any person
skilled in this art is enabled to make and use the same, this
enablement being provided in particular for the subject matter of
the appended claims, which make up a part of the original
description and including a composition comprising, in a
physiologically acceptable medium, at least one xanthine base or a
plant extract containing it, at least one polyurethane powder, and
at least one non-ionic dimethicone copolyol. Also fully enabled is
a cosmetic method for combating cellulite and/or "orange-peel" skin
and/or slimming the figure, comprising the topical application to
the skin of a composition according to the invention. In a
preferred embodiment, the skin to which the composition is applied
is skin showing signs of cellulite, or skin areas that commonly
show cellulite with the aging process, etc.
[0061] As used above, the phrases "selected from the group
consisting of," "chosen from," and the like include mixtures of the
specified materials.
[0062] All references, patents, applications, tests, standards,
documents, publications, brochures, texts, articles, etc. mentioned
herein are incorporated herein by reference. Where a numerical
limit or range is stated, the endpoints are included. Also, all
values and subranges within a numerical limit or range are
specifically included as if explicitly written out. Terms such as
"contain(s)" and the like as used herein are open terms meaning
`including at least` unless otherwise specifically noted.
[0063] The above description is presented to enable a person
skilled in the art to make and use the invention, and is provided
in the context of a particular application and its requirements.
Various modifications to the preferred embodiments will be readily
apparent to those skilled in the art, and the generic principles
defined herein may be applied to other embodiments and applications
without departing from the spirit and scope of the invention. Thus,
this invention is not intended to be limited to the embodiments
shown, but is to be accorded the widest scope consistent with the
principles and features disclosed herein.
* * * * *